Summary The effect of 17 P-oestradiol on a "receptor positive" and on a "receptor negative" human breast carcinoma grown in nude mice was studied. Experimental growth data were used to determine the effect on tumour growth. Flow The tumours were serially grown in nude mice and were transferred to our laboratory in the 11th and 24th transplant generations of the post menopausal and premenopausal carcinomas, respectively. The present investigations were performed on tumours from passage 17 (T61) and 34 (T60) in nude mice.
The basic mechanism of action of hormone therapy leading to tumour regression is not clearly understood. It has been shown that hormones induce cell kinetic changes in hormone sensitive tumour cells in vitro (Lippmann et al., 1976; Weichselbaum et al., 1978) and in vivo (Nordenskj6ld et al., 1976; Dao et al., 1982) , but whether the treatment acts by a suppression of cell proliferation or by a cytotoxic action resulting in cell death remains to be established.
Flow cytometric DNA analysis (FCM) has been introduced as a method for obtaining rapid information on cell cycle changes induced by radiotherapy and chemotherapy in experimental tumours (Spang-Thomsen et al., 1982; Gohde et al., 1975) , and by chemotherapy in clinical tumours (Vindel0v et al., 1982a) .
The present paper describes the effect of 17f-oestradiol on an oestrogen and progesterone receptor-positive and on an oestrogen and progesterone receptor-negative human breast carcinoma grown in castrated male nude mice. Experimental growth data were used to determine on the effect on tumour growth, and FCM analysis of tumour tissue obtained by sequential fine needle aspirations was used to estimate the effect on the cell cycle. In the receptor-positive breast carcinoma, oestradiol induced complete tumour regression and characteristic cell cycle changes. In the receptornegative breast carcinoma, the treatment had no effect on growth or on cell cycle kinetics.
The results suggest a relationship between the cell cycle pertubations and the cell killing effect of oestradiol, and thus indicate that FCM may be used in the early assessment of the clinical response to oestradiol treatment.
Materials and methods

Tumours
The two human breast carcinomas studied were kindly supplied by Dr The mice were treated with 1 mg 17f,-oestradiol (0.1 ml Progynon depot®' 10 mg ml -1, Schering AG, Berlin), as a single i.m. dose into the thigh. The tumours investigated comprised 20 treated and 12 untreated control tumours of T6 1, and 18 treated and 18 untreated controls of T60. The treatment was given at day 44 after transplantation in mice bearing T61 and at day 34 in mice bearing T60.
In a separate experiment, the serum oestradiol level in treated mice was determined by radioimmunoassay (Emment et al., 1972) . The assay was performed daily during the first 8 days after treatment. The serum concentrations of oestradiol varied from 1.36 x 10-7M at Day 1 (peak concentration) to 0.24 x 10-7 M at Day 8.
Receptor assay: Tumour samples for oestradiol and progesterone receptor assay were frozen immediately after excision and stored at -80°C. The receptor level determinations were conducted using the dextrancoated charcoal assay method (E.O.R.T.C., Breast Co-operative Group, 1980) . The receptor content and the dissociation constants were determined according to the method of Scatchard (1949) . A positive oestradiol or progesterone receptor assay was taken to be . 10 fmol mg-1 of cytosol protein. In the present investigation, 4 untreated T61 and 2 untreated T60 tumours were analyzed for receptor content.
Flow cytometric DNA analysis: The samples for FCM were obtained by sequential fine-needle aspirations. The aspiration procedure, storage of aspirates, and staining by propidiumiodide were performed as previously described (Vindel0v et al., 1977; 1982b; 1982c) . The flow cytometer used was a FACS III cell sorter (Becton Dickinson, Sunnyvale, CA.). The cellular DNA content was expressed as the DNA index (Barlogie et al., 1976) determined by the use of two internal standards (Vindel0v et al., 1982d) . The percentage of cells in the cycle phases was determined by a statistical analysis of the DNA distribution (Christensen et al., 1978) .
Growth data: Tumour measurements were used to construct rectilinear growth curves according to a transformed Gompertz function (Spang-Thomsen et al., 1980) . On the basis of this function, two regression lines were constructed for all growth curves, one before and one after treatment. Six experimental points were used for the determination of each of these lines. Normalized growth curves for each of the two breast carcinomas were constructed by correcting all growth data with the difference between the common mean tumour size at the time of treatment and the mean tumour size at the time of treatment in the individual treatment groups (Spang-Thomsen et al., 1981) .
Results
Figures 1 and 2 show the mean transformed Gompertz growth curves of the two breast carcinomas. The solid lines represent the calculated mean regression lines. Figure 1 indicates that oestradiol induced a substantial change in the growth of T61 tumours, resulting in the complete regression of all tumours. The tumour shrinkage commenced -12 days after treatment. Some tumours were observed for 75 days after treatment, and no regrowth was observed.
In the T60 tumour (Figure 2 ), the growth was unaffected by hormone treatment. The difference between the levels of the post-treatment growth seen to the right of the G2 + M peak in the histograms (Figure 3 b and c) . lines of controls and treated T60 tumours was not significant (t = 1.32P > 0.05).
Representative sequences of DNA distributions from the two carcinomas are shown in Figure 3 , and the percentage of cells in the cell cycle phases is plotted in Figure 4 as It has been demonstrated in in vitro investigations of human mammary cancer cells that the inhibitory effect of oestradiol on growth is associated with a decrease in the number of cells in the S phase (Lippman et al., 1976; Weichselbaum et al., 1978) . In the present investigation, the inhibitory effect on growth in tumour T61 was accompanied by an increase in the S phase fraction. However, the FCM results cannot be used to determine the extent to which the cells accumulated in S have stopped their DNA synthesis, and thus are proliferatively dead. This aspect is currently under investigation. It is of particular interest that the effect of oestradiol was associated with an S phase accumulation followed by a subsequent formation of polyploid cells, since the effect of tamoxifen, a non-sterodial anti-oestrogen, has been demonstrated to be associated with an accumulation of cells in the G1 phase of the cell cycle (Sutherland & Taylor, 1981) . Thus, these different observations on cell kinetics favour the hypothesis that oestradiol and tamoxifen have different sites of action (Butler et al., 1981) .
An evaluation of the response to endocrine therapy in patients with breast cancer is at present based on treatment-induced changes in tumour size, the only parameter available. This study has shown that oestradiol induced characteristic cell cycle changes in a hormone responsive tumour but not in a hormone unresponsive tumour, and that the changes could be monitored by FCM prior to the reduction in tumour size. Since the FCM method is simple and results are available a few hours after the biopsy, the present results indicate that the FCM method may prove applicable for an objective, early, and rapid evaluation of tumour response to hormone treatment in human breast cancer patients with tumours accessible for fineneedle aspiration.
Human solid tumours may be heterogeneous and constitute cell populations with varying sensitivity to anti-cancer treatment (Tropez et al., 1979; Engelholm et al., 1982) . Furthermore, heterogeneity has been demonstrated among metastases originating from the same primary tumour (Webster et al., 1978; Brennan et al., 1979 
